After numerous IL-2 failures there are glimmers of hope for the group’s contender, MDNA11.

First-in-human study initiations feature variations on well-trodden targets, plus a minor hiccup for OncoC4.

Early data with the group’s personalised project intrigue, but Transgene has a long road ahead.

One of the first human datasets concerning an ATM inhibitor shows glioblastoma’s intractability.

The company's comparison of its ADCs to Enhertu seems farfetched.

Selectively hitting PARP1 is meant to reduce toxicity, and arguably the Petra trial shows this.

Two pancreatic cancer trials will read out this quarter, but after a string of failures with the project they look like a long shot.

Fuelled with a $500m Summit windfall Akeso advances its lead bispecific.